Apollo Endosurgery (APEN) Stock Forecast, Price & News

Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

Is Apollo Endosurgery a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apollo Endosurgery stock.
View analyst ratings for Apollo Endosurgery or view top-rated stocks.

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Apollo Endosurgery.

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery, Inc. (NASDAQ:APEN) issued its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.21) EPS for the quarter, hitting analysts' consensus estimates of ($0.21). The biotechnology company earned $16.66 million during the quarter, compared to analyst estimates of $15.69 million. Apollo Endosurgery had a negative net margin of 43.31% and a negative trailing twelve-month return on equity of 95.87%. During the same period in the prior year, the firm earned ($0.17) EPS.
View Apollo Endosurgery's earnings history.

What guidance has Apollo Endosurgery issued on next quarter's earnings?

Apollo Endosurgery issued an update on its FY 2022 earnings guidance on Tuesday, March, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $73 million-$75 million, compared to the consensus revenue estimate of $73.52 million.

What price target have analysts set for APEN?

5 analysts have issued 1 year target prices for Apollo Endosurgery's shares. Their forecasts range from $10.00 to $15.00. On average, they expect Apollo Endosurgery's share price to reach $12.80 in the next year. This suggests a possible upside of 174.1% from the stock's current price.
View analysts' price targets for Apollo Endosurgery or view top-rated stocks among Wall Street analysts.

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the following people:

• Mr. Charles S. McKhann, CEO, Pres & Director (Age 53, Pay $963.53k)
• Mr. Jeffrey G. Black, CFO, Sec. & Treasurer (Age 53, Pay $524.02k) (LinkedIn Profile)
• Mr. John J. Molesphini, Exec. VP of Operations (Age 64, Pay $502.58k)
• Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
• Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
• Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
• Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
• Dr. Christopher J. Gostout M.D., Co-Founder & Chief Medical Officer (Age 71)
• Mr. Sydney Chung M.D., Co-Founder and Innovation Partner
• Dr. Pankaj Jay Pasricha FACP, M.D., MBBS, Co-Founder

Who are some of Apollo Endosurgery's key competitors?

Some companies that are related to Apollo Endosurgery include Bioventus (BVS), Pulmonx (LUNG), Cardiovascular Systems (CSII), UFP Technologies (UFPT), Alpha Tau Medical (DRTS), Surmodics (SRDX), Orthofix Medical (OFIX), SI-BONE (SIBN), Inovio Pharmaceuticals (INO), MiMedx Group (MDXG), Sight Sciences (SGHT), IRadimed (IRMD), Nyxoah (NYXH), Anika Therapeutics (ANIK) and SeaSpine (SPNE).
View all of APEN's competitors.

What other stocks do shareholders of Apollo Endosurgery own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a number of institutional and retail investors. Top institutional shareholders include CPMG Inc (9.70%), Nantahala Capital Management LLC (9.25%), Gagnon Securities LLC (3.80%), Vanguard Group Inc. (3.35%), Citigroup Inc. (2.85%) and Silverarc Capital Management LLC (2.50%). Company insiders that own Apollo Endosurgery stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends for Apollo Endosurgery.

Which major investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Renaissance Technologies LLC, Parkman Healthcare Partners LLC, Nantahala Capital Management LLC, Russell Investments Group Ltd., Gilder Gagnon Howe & Co. LLC, Calamos Advisors LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Apollo Endosurgery or view top insider-selling stocks.

Which major investors are buying Apollo Endosurgery stock?

APEN stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Invesco Ltd., Silverarc Capital Management LLC, Goldman Sachs Group Inc., Vanguard Group Inc., Bank of New York Mellon Corp, State Street Corp, and CPMG Inc. Company insiders that have bought Apollo Endosurgery stock in the last two years include Cpmg Inc, Jeffrey G Black, John R Barr, Neil Gagnon, and R Kent Mcgaughy Jr.
View insider buying and selling activity for Apollo Endosurgery or or view top insider-buying stocks.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $4.67.

How much money does Apollo Endosurgery make?

Apollo Endosurgery has a market capitalization of $187.97 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24.68 million in net income (profit) each year or ($0.820010) on an earnings per share basis.

How many employees does Apollo Endosurgery have?

Apollo Endosurgery employs 202 workers across the globe.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is www.apolloendo.com.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 279-5100, via email at [email protected], or via fax at 858-678-0900.